Results 51 to 60 of about 13,103,023 (178)

Real-life Outcomes of Tenofovir Disoproxil Fumarate Monotherapy in Nucleos(t)ide Analogue-naive and Nucleos(t)ide Analogue-experienced Chronic Hepatitis B Patients: A Single-center Experience [PDF]

open access: yes, 2016
Objective: The aim of the study was to evaluate the long-term results of treatment efficacy and safety in nucleos(t)ide analogue-naive (NA-naive) and NA-experienced chronic hepatitis B (CHB) patients receiving tenofovir disoproxil fumarate (TDF ...
TOKA, ONUR   +9 more
core   +1 more source

Host genetic factors in predicting response status in chronic hepatitis B patients discontinuing nucleos(t)ide analogs. [PDF]

open access: yesSaudi J Gastroenterol, 2018
Background/Aims: The optimal duration of nucleos(t)ide analogs (NAs) therapy in chronic hepatitis B (CHB) patients remains unsatisfactory. Previous studies have confirmed the important role of host genetic factors in determining the outcome of HBV ...
Li T   +6 more
europepmc   +2 more sources

Pros and cons of peginterferon versus nucleos(t)ide analogues for treatment of chronic hepatitis B [PDF]

open access: yes, 2010
The emergence of new and more potent treatment options has markedly changed the treatment landscape of chronic hepatitis B. Both peginterferon and nucleos(t)ide analogues have considerable advantages and limitations, and current treatment guidelines ...
Janssen, HLA   +7 more
core   +1 more source

Oligonucleotide and RNA-targeted therapeutics for chronic hepatitis B: Antigen reduction, delivery, and functional cure strategies. [PDF]

open access: yesMol Ther Nucleic Acids
Chronic hepatitis B (CHB) remains difficult to cure because nucleos(t)ide analogs suppress hepatitis B virus (HBV) replication but do not eliminate covalently closed circular DNA (cccDNA) or integrated HBV DNA, which sustain viral RNA and hepatitis B ...
Meng X, Mahmood F, Li H, Zhou T.
europepmc   +2 more sources

Gemcitabine and Nucleos(t)ide Synthesis Inhibitors Are Broad-Spectrum Antiviral Drugs that Activate Innate Immunity

open access: yes, 2018
Nucleoside analogs have been frequently identified as antiviral agents. In recent years, gemcitabine, a cytidine analog in clinical use for the treatment of many solid tumors, was also shown to have antiviral activity against a broad range of viruses ...
Sungchan Cho   +5 more
core   +1 more source

Mixed treatment comparison meta-analysis evaluating the relative efficacy of nucleos(t)ides for treatment of nucleos(t)ide-naive patients with chronic hepatitis B [PDF]

open access: yes, 2010
Background/aims Five nucleoside/nucleotide treatments are now available for chronic hepatitis B (CHB). This meta-analysis aimed to assess the relative efficacy of adefovir, entecavir, lamivudine, telbivudine, tenofovir disoproxil fumarate (TDF), and ...
Carrie Fidler   +2 more
core   +1 more source

A scoring model predicts hepatitis B e antigen seroconversion in chronic hepatitis B patients treated with nucleos(t)ide analogs: real-world clinical practice

open access: yesInternational Journal of Infectious Diseases, 2017
Aim: This study developed and validated a non-invasive scoring model to predict 1-year hepatitis B e antigen (HBeAg) seroconversion in response to nucleos(t)ide analog (NA) treatment in NA-naïve patients with HBeAg-positive chronic hepatitis B (CHB ...
Mingfan Geng   +9 more
doaj   +1 more source

High percentage atypical hepatocellular carcinoma in chronic hepatitis B patients treated with nucleos(t)ide analogs. [PDF]

open access: yesMedicine (Baltimore), 2019
Abstract Nucleos(t)ide analogs are used for preventing liver cirrhosis in chronic hepatitis B patients, but the risk factors of hepatocellular carcinoma (HCC) in these patients remain unclear. We designed this retrospective cohort study, the aim is to determine the risk factors for HCC development and its image presentation ...
Lin CC   +9 more
europepmc   +3 more sources

Minimal residual viremia in HBeAg positive individuals treated with nucleos(t)ide analogues.

open access: yes, 2013
Minimal residual viremia in HBeAg positive individuals treated with nucleos(t)ide analogues.
Melanie Maier (427543)   +5 more
core   +1 more source

SAMHD1 Is a Modulator of Nucleos(t)ide Analogues’ Efficacy

open access: yes, 2020
Nucleos(t)ide analogues are commonly used in the treatment of infectious disease and cancer. SAMHD1 is a deoxyribonucleotide (dNTP) triphosphohydrolase which is involved in the regulation of the intracellular dNTP pool, whose function has been linked to ...
Edurne Garcia-Vidal   +9 more
core   +1 more source

Home - About - Disclaimer - Privacy